Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PF-04136309 Clear all
Completed Phase 1 Interventional

FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT01413022
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil, laboratory biomarker analysis, flow cytometry, immunohistochemistry staining method, pharmacological study, PF-04136309
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Nov 5, 2026, 6:11 AM EST
Terminated Phase 2 Interventional Results available

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

NCT02732938
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
PF-04136309, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Nov 5, 2026, 6:11 AM EST
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee

NCT00689273
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04136309, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
DeLand, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Nov 5, 2026, 6:11 AM EST